Search

Your search keyword '"Motohiro Ebisawa, MD"' showing total 3 results
Start Over Author "Motohiro Ebisawa, MD" Topic anaphylaxis
3 results on '"Motohiro Ebisawa, MD"'

1. Allergic and hypersensitivity condition in the International Patients’ Summary (IPS) standard: The need of updates through the International Classification of Diseases (ICD)-11

Author

Luciana Kase Tanno, MD, PhD, Alain Perie, PhD, Jonathan A. Bernstein, MD, James L. Sublett, MD, Karapet Davtyan, MD, MPH, MBA, Frederic Berard, MD, PhD, Ruby Pawankar, MD, PhD, Marylin Valentin Rostan, MD, Herberto Chong, MD, PhD, Anahi Yañez, MD, Ignacio J. Ansontegui, MD, PhD, Motohiro Ebisawa, MD, PhD, Gary W.K. Wong, MD, PhD, Mario Morais-Almeida, MD, Bryan Martin, MD, Yann Briand, PhD, and Pascal Demoly, MD, PhD

Subjects
Allergy, Anaphylaxis, Classification, Coding, Epidemiology, Hypersensitivity, Immunologic diseases. Allergy, RC581-607
Abstract

In 2010, the United States Human and Health Services (US HHS) and the European Union's (EU) Directorate General for Communications Networks, Content and Technology signed a memorandum of understanding to stimulate cooperation surrounding health-related information communications technology. The key project that emerged from this agreement is the International Patient Summary (IPS), intended to provide succinct clinically relevant patient summaries, which are generalizable and condition-independent, that can be readily used by all clinicians for the care of patients. Although allergies are included in the main information required by the IPS library and framework, it is misrepresented which leads to underdiagnosis or misdiagnosis of patients suffering from allergic and hypersensitivity conditions (A/H). The French and Montpellier World Health Organization (WHO) Collaborating Centres have provided arguments for supporting representation of A/H in the IPS. These are based on the relevance of the new classification of A/H in the WHO International Classification of Diseases 11th version (ICD-11), and the need for alignment of eHealth tools with harmonized health information. We first present the A/H in the IPS initiative with the mission of producing an international information system that can be used globally in electronic health records to standardize clinical diagnoses and facilitate communication between clinicians caring for patients with A/H diseases. It is believed this initiative will provide a strong voice for the allergy community and an effective process for improving the quality of health data that will optimize medical care for our patients worldwide.

Published
2024
Full Text
View/download PDF

2. Updated grading system for systemic allergic reactions: Joint Statement of the World Allergy Organization Anaphylaxis Committee and Allergen Immunotherapy Committee

Author

Paul J. Turner, MD, PhD, Ignacio J. Ansotegui, MD, PhD, Dianne E. Campbell, MD, PhD, Victoria Cardona, MD, PhD, Stuart Carr, MD, Adnan Custovic, MD, PhD, Stephen Durham, MD, Motohiro Ebisawa, MD, PhD, Mario Geller, MD, Alexei Gonzalez-Estrada, MD, Paul A. Greenberger, MD, Elham Hossny, MD, PhD, Carla Irani, MD, Agnes S.Y. Leung, MD, Michael E. Levin, MD, PhD, Antonella Muraro, MD, John J. Oppenheimer, MD, José Antonio Ortega Martell, MD, Guillaume Pouessel, MD, Manuel J. Rial, MD, PhD, Gianenrico Senna, MD, PhD, Luciana K. Tanno, MD, PhD, Dana V. Wallace, MD, Margitta Worm, MD, PhD, and Mário Morais-Almeida, MD, PhD

Subjects
Adverse events, Allergen immunotherapy, Anaphylaxis, Clinical trials, Safety reporting, Immunologic diseases. Allergy, RC581-607
Abstract

There is a lack of consensus over the description and severity assignment of allergic adverse reactions to immunotherapy, although there seems to be a consensus at least in terms of using the World Allergy Organization (WAO) grading systems to describe local adverse events for Sublingual Immunotherapy (SLIT) and Systemic Allergic Reactions (SARs) to Subcutaneous Immunotherapy (SCIT) amongst the major national/regional allergy societies. In this manuscript, we propose a modification of the previous WAO Grading system for SARs, which aligns with the newly-proposed Consortium for Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions in Food Allergy (version 3.0). We hope this can facilitate a unified grading system appropriate to SARs due to allergen immunotherapy, independent of allergen and route of administration, and across clinical and research practice.

Published
2024
Full Text
View/download PDF

3. Global disparities in availability of epinephrine auto-injectors

Author

Luciana Kase Tanno, MD, PhD, Margitta Worm, MD, PhD, Motohiro Ebisawa, MD, PhD, Ignacio J. Ansotegui, MD, PhD, Gianenrico Senna, MD, PhD, Stanley Fineman, MD, PhD, Mario Geller, MD, Alexei Gonzalez-Estrada, MD, Dianne E. Campbell, MBBS, FRACP, PhD, Agnes Leung, MBChB, Antonella Muraro, MD, PhD, Michael Levin, MD, PhD, Jose Antonio Ortega Martell, MD, PhD, Marco Caminati, MD, Pavel Kolkhir, MD, Duy Le Pham, MD, PhD, Razvigor Darlenski, MD, PhD, Ignacio Esteban-Gorgojo, MD, Manuel Rial, MD, PhD, Ivana Filipovic, MD, Sergio E. Chiarella, MD, Lyda Cuervo-Pardo, MD, Christina Kwong, MD, Cezar Fireth Pozo-Beltran, MD, Tu HK. Trinh, MD, PhD, Paul A. Greenberger, MD, Paul J. Turner, FRCPCH, PhD, Bernard Yu-Hor Thong, MBBS, FRCP (Edin), Bryan Martin, MD, and Victoria Cardona, MD, PhD

Subjects
Anaphylaxis, Adrenaline, Adrenaline auto-injector, Epinephrine auto-injector, Management, Treatment, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Anaphylaxis is the most severe clinical presentation of acute systemic allergic reactions and can cause death. Given the prevalence of anaphylaxis within healthcare systems, it is a high priority public health issue. However, management of anaphylaxis – both acute and preventative – varies by region. Methods: The World Allergy Organization (WAO) Anaphylaxis Committee and the WAO Junior Members Steering Group undertook a global online survey to evaluate local practice in the diagnosis and management of anaphylaxis across regions. Results: Responses were received from WAO members in 66 countries. While intramuscular epinephrine (adrenaline) is first-line treatment for anaphylaxis, some countries continue to recommend alternative routes in contrast to guidelines. Epinephrine auto-injector (EAI) devices, prescribed to individuals at ongoing risk of anaphylaxis in the community setting, are only available in 60% of countries surveyed, mainly in high-income countries. Many countries in South America, Africa/Middle-East and Asian-Pacific regions do not have EAI available, or depend on individual importation. In countries where EAIs are commercially available, national policies regarding the availability of EAIs in public settings are limited to few countries (16%). There is no consensus regarding the time patients should be observed following emergency treatment of anaphylaxis. Conclusion: This survey provides a global snapshot view of the current management of anaphylaxis, and highlights key unmet needs including the global availability of epinephrine for self-injection as a key component of anaphylaxis management.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results